Need to update cardiological guidelines to prevent COVID-19 related myocardial infarction and ischemic stroke by Nucera, Gabriella et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 1897-5593
e-ISSN: 1898-018X
Need to update cardiological guidelines to prevent COVID-19
related myocardial infarction and ischemic stroke
Authors:  Gabriella Nucera, Francesco Chirico, Zubaid Rafique, Natasza Gilis-
Malinowska, Aleksandra Gasecka, Nataliia Litvinova, Benjamin Wang, Olayinka
Ilesanmi, Michal Pruc, Milosz J. Jaguszewski, Lukasz Szarpak
DOI: 10.5603/CJ.a2021.0120




This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Articles in "Cardiology Journal" are listed in PubMed. 
Powered by TCPDF (www.tcpdf.org)
Need to update cardiological guidelines to prevent COVID-19 related myocardial 
infarction and ischemic stroke
Gabriella Nucera et al., Myocardial infarction and stroke due to COVID-19
Gabriella Nucera1, Francesco Chirico2, 3, Zubaid Rafique4, Natasza Gilis-Malinowska5 , 
Aleksandra Gasecka6, Nataliia Litvinova7, Benjamin Wang8, Olayinka S. Ilesanmi9, 10, Michal 
Pruc11, 12, Milosz J. Jaguszewski5, Lukasz Szarpak11, 13, 14 
1Department of Emergency, Fatebenefratelli Hospital, ASST Fatebenefratelli and Sacco, 
Milan, Italy
2Post-graduate School of Occupational health, Università Cattolica del Sacro Cuore, Rome, 
Italy
3Health Service Department, Italian State Police, Ministry of the Interior, Milan, Italy
4Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, 
TX, United States
5First Department of Cardiology, Medical University of Gdansk, Poland
6Laboratory of Experimental Clinical Chemistry, Amsterdam University Medical Center, 
Amsterdam, the Netherlands
7European Medical School, International European University, Kiev, Ukraine
8UC Davis Graduate School of Management, Davis, CA, United States
9Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, 
Oyo State, Nigeria
10Department of Community Medicine, College of Medicine, University College Hospital, 
Ibadan, Oyo State, Nigeria
11Polish Society of Disaster Medicine, Warsaw, Poland
12Institute of Outcomes Research, Polonia University, Czestochowa, Poland
13Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland
14Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, 
Poland
This paper was guest edited by Prof. Togay Evrin
Address for correspondence: Dr. Francesco Chirico, Health Service Department, Italian State 
Police, Ministry of the Interior, Via Umberto Cagni, 21 20162 Milano, Italy, e-mail: 
francesco.chirico@unicatt.it
Novel coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) has become a challenge for the health care system worldwide and continues to
have a significant impact on both the lives of people around the world and the functioning of 
medical services [1, 2]. One-third of patients hospitalized due to severe coronavirus disease 
2019 (COVID-19) develops macrovascular thrombotic complications, including venous 
thromboembolism, myocardial injury/infarction, and stroke [3]. Both the risk of stroke and 
myocardial infarction  caused by COVID-19 has posed huge pressures on medical services 
during the pandemic. Beyond the COVID-19 pandemic period itself, the post-pandemic 
effects can also be dramatic for healthcare systems, because rehabilitation services shall 
manage patients recovering from severe COVID-19 with post-intensive care syndromes, 
which results in physical deconditioning and cognitive impairments, patients with comorbid 
conditions, and other patients requiring physical therapy during the outbreak.
Evidence from a study among 86,742 COVID-19 cases revealed an increase in rates of
heart attack by nearly 5 times. In addition, the risk of a first stroke due to blockage of blood 
vessels increased three to six times which was sustained for at least 4 weeks [4]. 
Importantly, the study did not include people who had previously had a heart attack or 
stroke in the past, which may suggest that the risk of another heart attack or stroke in people 
who have had one may probably be even significantly higher.
COVID-19 affects the inner surfaces of the veins and arteries, causing inflammation of
blood vessels (endothelium) followed by damage to very small vessels and culmination as 
blood clots, leading to disturbances in blood flow to the heart or blood clots in other parts of 
the body. This results in a stroke or heart attack. 
Direct myocardial injury by viral involvement of cardiomyocytes, indirect and direct 
inflammatory damage, O2 supply–demand imbalance, and increase of atherothrombotic events
due to inflammatory destabilization of atheromatous plaques may result in myocardial 
infarction and/or heart failure [5–7].
Acute cerebrovascular disease, particularly ischemic stroke is caused by involvement 
of large vessel occlusion, multi-territory stroke, and otherwise uncommonly affected vessels. 
On the contrary, small-vessel brain disease, cerebral venous thrombosis, and intracerebral 
hemorrhage appear to be less frequent [8].
Hypertension seems to enhance the inflammatory profile in patients with SARS-CoV-2
infection [5], and hyperglycemia might modulate immune and inflammatory responses, thus 
predisposing patients to severe COVID-19 and possible lethal outcomes [9]. It is not a 
coincidence that hypertension (56.6%) and diabetes (33.8%) are the most prevalent 
comorbidities among individuals with COVID-19, who require hospitalization [5]. 
To date, effective therapies against COVID-19 are not currently available. All the 
governments have invested their efforts on vaccines, which are considered as the only 
effective weapons to curb the COVID-19 pandemic. However, the onset of new SARS-CoV-2
variants, the high vaccine hesitancy rates in rich countries, and the huge vaccination rate 
disparity between rich and poor countries are delaying the mass vaccination campaign 
worldwide.  
Therefore, data on COVID-19-related myocardial infarction and ischemic stroke are 
worrying and indicate the need to implement prophylaxis in the form of anticoagulants, which
could be used routinely in the event of thrombosis caused by COVID-19. For this reason, 
cardiological guidelines for the treatment of post-COVID-19 syndromes should also be 
established, to drive healthcare workers especially when high-risk categories such as older, 
obese and patients affected by co-morbidities are affected by COVID-19 infection.
This could reduce the incidence and mortality associated with COVID-19-related 
acute myocardial injury or stroke, and prevent severe forms of COVID-19 infection 
associated with coagulation changes and the risk of thrombosis, particularly in the features of 
pulmonary embolism and acute respiratory distress syndrome.
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